Results 11 to 20 of about 316,749 (274)

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes

International Journal of Environmental Research and Public Health, 2021
Diabetes mellitus (DM) is a strong risk factor for the development of cardiovascular diseases such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease (PAD). In the population of people living with DM, PAD is characterised
Grzegorz K. Jakubiak, N. Pawlas, G. Cieślar, Agata Stanek   +3 more
semanticscholar   +1 more source

Pathogenetic mechanisms of repeated adverse cardiovascular events development in patients with coronary heart disease: the role of chronic inflammation [PDF]

Folia Medica, 2023
Stent restenosis is the most unfavorable complication of interventional treatment for coronary heart disease. We already know from various literature sources that the causes for stent restenosis in patients are both mechanical damage (partial opening ...
Irina Starodubtseva, Maria Meshkova, Anna Zuikova   +2 more
doaj   +3 more sources

In-stent restenosis and stented-territory infarction after carotid and vertebrobasilar artery stenting

BMC Neurology, 2023
Background Prognosis after vertebrobasilar stenting (VBS) may differ from that after carotid artery stenting (CAS). Here, we directly compared the incidence and predictors of in-stent restenosis and stented-territory infarction after VBS and compared ...
Jae-Chan Ryu, Jae-Han Bae, Sang Hee Ha, Boseong Kwon, Yunsun Song, Deok Hee Lee, Jun Young Chang, Dong-Wha Kang, Sun U. Kwon, Jong S. Kim, Bum Joon Kim   +10 more
doaj   +1 more source

Restenosis begets restenosis: implications for stent selection [PDF]

Netherlands Heart Journal, 2008
Identifying the risk for restenosis is of critical importance in the stent selection process of patients undergoing percutaneous coronary intervention (PCI). Therefore, we sought to determine if a history of clinical recurrence (CR) after PCI increases the risk of CR after treatment of a de novo lesion in another coronary artery.We retrospectively ...
Wijpkema, J. S., Anthonio, R. L., Jessurun, G. A. J., Dijk, W. A., Tio, R. A., Zijlstra, F.   +5 more
openaire   +3 more sources

Periodontitis Is Associated With Risk of Conventional Stent Restenosis: Pilot Case-Control Study

Frontiers in Dental Medicine, 2021
Objectives: Percutaneous coronary angioplasty with stent implantation has been established as the main form of treatment of atherosclerosis. However, 16 to 44% of patients may evolve with stent restenosis.
Raphael Osugue, Nidia C. Castro dos Santos, Nidia C. Castro dos Santos, Cassia F. Araujo, Flavio X. de Almeida, Magda Feres, Mauro P. Santamaria   +6 more
doaj   +1 more source

Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis.

Journal of the American College of Cardiology, 2020
BACKGROUND In patients with coronary in-stent restenosis (ISR) requiring reintervention, it is unclear if the choice of treatment should depend on whether the restenotic stent was a bare-metal stent (BMS) or a drug-eluting stent (DES).
D. Giacoppo, F. Alfonso, Bo Xu, B. Claessen, T. Adriaenssens, C. Jensen, M. Pérez-Vizcayno, D. Kang, R. Degenhardt, L. Pleva, J. Baan, J. Cuesta, Duk‐Woo Park, P. Kukla, P. Jiménez-Quevedo, M. Unverdorben, R. Gao, C. Naber, Seung‐Jung Park, J. Henriques, A. Kastrati, R. Byrne   +21 more
semanticscholar   +1 more source

1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration.

JACC: Cardiovascular Interventions, 2022
OBJECTIVES This study aimed to investigate the 1-year risk of restenosis and aneurysmal degeneration and explore the associated factors after femoropopliteal implantation of fluoropolymer-based drug-eluting stents (FP-DESs) for symptomatic ...
O. Iida, M. Takahara, Y. Soga, T. Yamaoka, M. Fujihara, D. Kawasaki, S. Ichihashi, A. Kozuki, S. Nanto, Y. Sakata, T. Mano   +10 more
semanticscholar   +1 more source

Design and testing of hydrophobic core/hydrophilic shell nano/micro particles for drug-eluting stent coating [PDF]

, 2018
In this study, we designed a novel drug-eluting coating for vascular implants consisting of a core coating of the anti-proliferative drug docetaxel (DTX) and a shell coating of the platelet glycoprotein IIb/IIIa receptor monoclonal antibody SZ-21.
A Arsiwala, A Bierhalz, A Tan, AW Heldman, B Almería, B O’brien, B O’Brien, C Stettler, CJ Pan, CJ Sweeney, CL Song, D Sun, DM Saylor, E Boersma, E Camenzind, ES Park, ES Thian, F Danhier, GY An, H Zhang, HG Wang, J Kanzer, J Riegger, J Yang, J Zhang, JB Slee, JJ Wykrzykowska, JM Lee, JV Natarajan, K Kolandaivelu, KH Bønaa, KS Lim, M Gawaz, M Zamani, M Zamani, MK Dong, MP Skinner, MT Ali, PS Douglas, PW Erruys, RH Müller, RK Aggarwal, RL Wilensky, S Freiberg, S Garg, S Hossfeld, S Jang, S Lee, S Mcginty, S Meng, S Puricel, S Yasuda, SJ Liu, T Inoue, T Nakano, TM Ko, U Baber, X Ma, X Wu, X Xi, Y Cao, YH Lee, Z Yang   +62 more
core   +1 more source

Stent-in-Stent Endovascular Correction in Right Internal Carotid Artery Restenosis: a Clinical Case

Креативная хирургия и онкология, 2021
Background. Carotid artery restenosis is a rare complication of carotid stenting. The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) reveals an in-stent restenosis rate of 0–6 %, a fairly low value given an extensive study ...
T. N. Khafizov, R. R. Khafizov, I. E. Nikolaeva, I. A. Idrisov, E. E. Abkhalikova, S. M. Karasev, D. R. Khafizova   +6 more
doaj   +1 more source

Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis

European Journal of Medical Research, 2023
Purpose To investigate the safety and efficacy of Enterprise stent angioplasty and risk factors for the prognoses in treating symptomatic severe posterior circulation atherosclerotic stenosis (SSPCAS).
Zhi-Long Zhou, Tian-Xiao Li, Liang-Fu Zhu, Li-Heng Wu, Min Guan, Zhen-Kai Ma, Yang-Hui Liu, Jin Qin, Bu-Lang Gao   +8 more
doaj   +1 more source